Are Peptides Legal in Utah? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Utah as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Utah attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Utah statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Utah has scheduled or banned on its own. The Utah Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Utah at a glance

State controlled-substances law: Utah Controlled Substances Act, Utah Code Title 58, Chapter 37; schedules at Utah Code 58-37-108 (formerly 58-37-4, recodified 6 May 2026) (le.utah.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (Utah Code 58-37-108(2)(c), Schedule III) (le.utah.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Utah Board of Pharmacy newsletter of May 2024 reported that the Division of Professional Licensing had issued citations for medspas dispensing compounded semaglutide in individual syringes, for dispensing practitioners acting out of scope, for compounding with semaglutide salts (not allowed by the FDA) and for 503A pharmacies compounding for office use, which requires a 503B outsourcing facility. It stated that compounding was legal only while the approved drugs were on the FDA shortage list. The May 2025 newsletter added no new rule (2024-05) (nabp.pharmacy)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Under the Utah Telehealth Act (Utah Code 26B-4-704) a telehealth provider is held to the same standards as in-person care, must establish a provider-patient relationship during the encounter, and must establish a diagnosis and identify contraindications from a documented clinical history before prescribing. There is no statutory in-person examination requirement, but a prescription based solely on an online questionnaire does not meet the standard. GLP-1 pens are prescribable by a Utah-licensed telehealth prescriber on that basis. (le.utah.gov)
State-level enforcement, 2023 to 2026: 3 actions found
Last verified: 28 September 2026, confidence high

The federal rules that apply in Utah, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Utah:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Utah. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Utah law adds

Utah's controlled-substances law (Utah Controlled Substances Act, Utah Code Title 58, Chapter 37; schedules at Utah Code 58-37-108 (formerly 58-37-4, recodified 6 May 2026)) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (le.utah.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Utah's schedules or in a Utah-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Growth hormone, somatropin and gonadotropin do not appear anywhere in Utah's schedules; Schedule III lists 27 named anabolic steroids. Utah also treats anything on the federal schedules as controlled, and HGH is not on those either, so only the federal HGH statute applies. (Utah Code 58-37-108(2)(c), Schedule III) (le.utah.gov)

Compounded semaglutide and tirzepatide

2024-05. The Utah Board of Pharmacy newsletter of May 2024 reported that the Division of Professional Licensing had issued citations for medspas dispensing compounded semaglutide in individual syringes, for dispensing practitioners acting out of scope, for compounding with semaglutide salts (not allowed by the FDA) and for 503A pharmacies compounding for office use, which requires a 503B outsourcing facility. It stated that compounding was legal only while the approved drugs were on the FDA shortage list. The May 2025 newsletter added no new rule. (nabp.pharmacy)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Utah medical board guidance specific to peptide therapy was located. A Utah prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Utah

No Utah provision on research peptides or HGH was found; unless a substance is in Utah's schedules or the federal schedules, Utah's possession offences do not reach it and the federal FDCA rules, which fall on the seller, apply. (le.utah.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Utah is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Under the Utah Telehealth Act (Utah Code 26B-4-704) a telehealth provider is held to the same standards as in-person care, must establish a provider-patient relationship during the encounter, and must establish a diagnosis and identify contraindications from a documented clinical history before prescribing. There is no statutory in-person examination requirement, but a prescription based solely on an online questionnaire does not meet the standard. GLP-1 pens are prescribable by a Utah-licensed telehealth prescriber on that basis. (le.utah.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Utah law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Utah

2026-04-01. A federal grand jury indicted Justin Bradley Watkins, a licensed osteopathic physician of Pleasant View, for receiving and selling misbranded drugs: peptides bought from China between February 2024 and April 2025, including tirzepatide, semaglutide, retatrutide, cagrilintide, BPC-157, TB-500, ipamorelin, CJC-1295, GHK-Cu and NAD+, relabelled and sold to more than 200 patients. The case was investigated by FDA criminal investigators together with Utah's Division of Professional Licensing. An indictment is an allegation. (justice.gov)
2025-02-19. Utah's attorney general joined the multistate letter urging the FDA to act against counterfeit and illegally sold GLP-1 drugs and the compounding pharmacies supplying that market. (naag.org)
2024-05. The Division of Professional Licensing issued citations (no names published) for medspas dispensing compounded semaglutide, out-of-scope dispensing, semaglutide salt compounding and 503A office-use compounding, per the Board of Pharmacy newsletter. (nabp.pharmacy)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. The controlled-substances chapter was renumbered in 2026 (58-37-4 became 58-37-108); older sources cite the old number. Utah is the one state so far where a peptide-prescribing physician faces federal charges brought with the state licensing division's help.

Frequently asked questions

Is BPC-157 legal in Utah?

Utah has not scheduled BPC-157, so possessing it is not a Utah offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Utah?

Under the Utah Telehealth Act (Utah Code 26B-4-704) a telehealth provider is held to the same standards as in-person care, must establish a provider-patient relationship during the encounter, and must establish a diagnosis and identify contraindications from a documented clinical history before prescribing. There is no statutory in-person examination requirement, but a prescription based solely on an online questionnaire does not meet the standard. GLP-1 pens are prescribable by a Utah-licensed telehealth prescriber on that basis. The Utah Board of Pharmacy position on compounded versions: The Utah Board of Pharmacy newsletter of May 2024 reported that the Division of Professional Licensing had issued citations for medspas dispensing compounded semaglutide in individual syringes, for dispensing practitioners acting out of scope, for compounding with semaglutide salts (not allowed by the FDA) and for 503A pharmacies compounding for office use, which requires a 503B outsourcing facility. It stated that compounding was legal only while the approved drugs were on the FDA shortage list. The May 2025 newsletter added no new rule.

Is HGH legal in Utah?

Only with a valid prescription for an approved use. Utah does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Utah fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.